List of Incyte patents

Patents where

Current Assignee

Name

Incyte

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10308644 Heterocyclic compounds as immunomodulators	Patent 10308644 was granted and assigned to Incyte on June, 2019 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	10308644	June 4, 2019
‌ US Patent 11866434 Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof	Patent 11866434 was granted and assigned to Incyte on January, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11866434	January 9, 2024
‌ US Patent 11866451 Salts and crystalline forms of a PD-1/PD-L1 inhibitor	Patent 11866451 was granted and assigned to Incyte on January, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11866451	January 9, 2024
‌ US Patent 11760756 Crystalline form of a PD-1/PD-L1 inhibitor	Patent 11760756 was granted and assigned to Incyte on September, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11760756	September 19, 2023
‌ US Patent 11780836 Process of preparing a PD-1/PD-L1 inhibitor	Patent 11780836 was granted and assigned to Incyte on October, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11780836	October 10, 2023
‌ US Patent 12024517 Salts of an FGFR inhibitor	Patent 12024517 was granted and assigned to Incyte on July, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	12024517	July 2, 2024
‌ US Patent 11753406 Salts of a PD-1/PD-L1 inhibitor	Patent 11753406 was granted and assigned to Incyte on September, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11753406	September 12, 2023
‌ US Patent 11407750 Derivatives of an FGFR inhibitor	Patent 11407750 was granted and assigned to Incyte on August, 2022 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11407750	August 9, 2022
‌ US Patent 7598257 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors	Patent 7598257 was granted and assigned to Incyte on October, 2009 by the United States Patent and Trademark Office.		Incyte	United States Patent and Trademark Office	7598257	October 6, 2009
‌ US Patent 11905292 Process and intermediates for preparing a JAK inhibitor	Patent 11905292 was granted and assigned to Incyte on February, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11905292	February 20, 2024
‌ US Patent 11780840 Tricyclic urea compounds as JAK2 V617F inhibitors	Patent 11780840 was granted and assigned to Incyte on October, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11780840	October 10, 2023
‌ US Patent 11466004 Solid forms of an FGFR inhibitor and processes for preparing the same	Patent 11466004 was granted and assigned to Incyte on October, 2022 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11466004	October 11, 2022
‌ US Patent 11472801 Crystalline forms of a FGFR inhibitor and processes for preparing the same	Patent 11472801 was granted and assigned to Incyte on October, 2022 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11472801	October 18, 2022
‌ US Patent 11014923 Bicyclic heterocycles as FGFR4 inhibitors	Patent 11014923 was granted and assigned to Incyte on May, 2021 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11014923	May 25, 2021
‌ US Patent 10906920 Heterocyclic compounds as immunomodulators	Patent 10906920 was granted and assigned to Incyte on February, 2021 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	10906920	February 2, 2021
‌ US Patent 11066394 Solid forms of an HPK1 inhibitor	Patent 11066394 was granted and assigned to Incyte on July, 2021 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11066394	July 20, 2021
‌ US Patent 11673894 Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors	Patent 11673894 was granted and assigned to Incyte on June, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11673894	June 13, 2023
‌ US Patent 11939331 Tricyclic heterocycles as FGFR inhibitors	Patent 11939331 was granted and assigned to Incyte on March, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11939331	March 26, 2024
‌ US Patent 11787793 Heterocyclic compounds as immunomodulators	Patent 11787793 was granted and assigned to Incyte on October, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11787793	October 17, 2023
‌ US Patent 11866435 Heterocyclic compounds as immunomodulators	Patent 11866435 was granted and assigned to Incyte on January, 2024 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11866435	January 9, 2024
‌ US Patent 10214528 Bicyclic heterocycles as FGFR4 inhibitors	Patent 10214528 was granted and assigned to Incyte on February, 2019 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	10214528	February 26, 2019
‌ US Patent 11299473 Benzimidazole and indole compounds and uses thereof	Patent 11299473 was granted and assigned to Incyte on April, 2022 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11299473	April 12, 2022
‌ US Patent 11767323 Tricyclic pyridone compounds as JAK2 V617F inhibitors	Patent 11767323 was granted and assigned to Incyte on September, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11767323	September 26, 2023
‌ US Patent 11542265 Pyrazolopyrimidine compounds and uses thereof	Patent 11542265 was granted and assigned to Incyte on January, 2023 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	11542265	January 3, 2023
‌ US Patent 10435405 Pyrazolopyridine compounds and uses thereof	Patent 10435405 was granted and assigned to Incyte on October, 2019 by the United States Patent and Trademark Office.	Incyte	Incyte	United States Patent and Trademark Office	10435405	October 8, 2019

...

Results per page:

401 results

0 selected

401 results

0 selected